HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Germline and/or somatic mutations in BRCA1/BRCA2 in other cancer types also confer selective sensitivity to PARP inhibitors. T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nat Med
Hauptverfasser: Davies, Helen, Glodzik, Dominik, Morganella, Sandro, Yates, Lucy R., Staaf, Johan, Zou, Xueqing, Ramakrishna, Manasa, Martin, Sancha, Boyault, Sandrine, Sieuwerts, Anieta M., Simpson, Peter T., King, Tari A., Raine, Keiran, Eyfjord, Jorunn E., Kong, Gu, Borg, Åke, Birney, Ewan, Stunnenberg, Hendrik G., van de Vijver, Marc J., Børresen-Dale, Anne-Lise, Martens, John W.M., Span, Paul N., Lakhani, Sunil R, Vincent-Salomon, Anne, Sotiriou, Christos, Tutt, Andrew, Thompson, Alastair M., Van Laere, Steven, Richardson, Andrea L., Viari, Alain, Campbell, Peter J, Stratton, Michael R., Nik-Zainal, Serena
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2017
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833945/
https://ncbi.nlm.nih.gov/pubmed/28288110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4292
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge